$671 Million is the total value of Bain Capital Life Sciences Investors, LLC's 10 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNST | New | CONSTELLATION PHARMACEUTICALS INC. | $133,016,000 | – | 2,823,529 | +100.0% | 19.84% | – |
| SVRA | New | SAVARA INC | $22,976,000 | – | 5,128,593 | +100.0% | 3.43% | – |
| XFOR | New | X4 PHARMACEUTICALS INC | $17,639,000 | – | 1,648,485 | +100.0% | 2.63% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, LP #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SAVARA INC | 19 | Q2 2024 | 6.4% |
| X4 PHARMACEUTICALS INC | 19 | Q2 2024 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 18 | Q2 2024 | 20.1% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| MERSANA THERAPEUTICS, INC. | 17 | Q2 2024 | 8.4% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| ANNEXON INC | 16 | Q2 2024 | 9.1% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-12 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.